ArticleJournal of neural transmission (Vienna, Austria : 1996)2019
Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A SERS-Based Antibody-Aptamer Sandwich Assay for Extracellular Vesicle-Associated Tau Detection Using Gold Nanoparticles.Advanced sensor research · 2025Article
- Article
- Protein Misfolding in the Pathogenesis and Diagnosis of Neurodegenerative Diseases (Review).Sovremennye tekhnologii v meditsine · 2025Review
- Identifying Protein-Protein Interaction or Protein Phosphorylation by Proximity Ligation Assay (PLA) in Endothelial Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Independent and joint associations between urinary polycyclic aromatic hydrocarbon metabolites and cognitive function in older adults in the United States.Frontiers in public health · 2024Article
- IL-34 exacerbates pathogenic features of Alzheimer's disease and calvaria osteolysis in triple transgenic (3x-Tg) female mice.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors.ACS chemical neuroscience · 2023Article
- Induction of Brain Insulin Resistance and Alzheimer's Molecular Changes by Western Diet.International journal of molecular sciences · 2022Article
- Tauopathies: new perspectives and challenges.Molecular neurodegeneration · 2022Review
- "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.Molecular neurodegeneration · 2021Review
- Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.Acta neuropathologica · 2021 · on this mapArticle
- BMP4 overexpression induces the upregulation of APP/Tau and memory deficits in Alzheimer's disease.Cell death discovery · 2021Article
- Milrinone Ameliorates the Neuroinflammation and Memory Function of Alzheimer's Disease in an APP/PS1 Mouse Model.Neuropsychiatric disease and treatment · 2021Article
- Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected.EMBO molecular medicine · 2020Article
- Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification.Alzheimer's research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the presence of extracellular amyloid plaques (senile plaques) and intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein. This process leads to neuronal degradation and neuronal death. Phosphorylation of tau protein at threonine 231 (p-tau231) has been shown to be characteristic in post-mortem brain tissue of patients with AD and it can be sensitively detected in cerebrospinal fluid (CSF). Therefore, it may serve as a biomarker to support the diagnosis of AD. In this study, we analysed how well p-tau231 could differentiate between patients suffering from dementia either due or not due to AD by a sandwich enzyme immunoassay. CSF p-tau231 was significantly higher in patients with dementia due to AD than in those with dementia due to other causes. In addition, we studied different factors affecting p-tau231 levels in CSF. We found that apolipoprotein E genotype influences p-tau231 CSF levels. Gender and age did not affect p-tau231 levels in CSF. Our findings indicate that p-tau231 levels in CSF can be a valuable marker for the clinical diagnosis of AD.
Indexed as
Identifiers
30767082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.